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Conclusion: Our results confirm the validity of PCXMC with 
rotational module also for particular geometrical conditions; 
patient dose can be evaluated based on patient equivalent 
diameter.  
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Purpose or Objective: Hodgkin's lymphoma (HL) is one of the 
most curable types of cancer. Most HL patients are young 
(average age of 32 years); long-term side effects of the 
treatment are becoming increasingly important. Infertility 
after treatment could have a high psychosocial burden for 
young patients. More, HL is one of the most common 
malignancies diagnosed during pregnancy. The aim of the 
present study is to measure dose to ovaries and uterus, 
during supra-diaphragmatic radiotherapy performed with 
different techniques (3DRT, IMRT, VMAT and helical IMRT- 
Tomotherapy®). 
 
Material and Methods: Dose measurements were performed 
using the plans of four different female patients, in 
reproductive age. The patients have been treated with 
chemotherapy and mediastinum irradiation (isocenter dose 
30 Gy). An adult anthropomorphic Alderson Rando phantom 
(Rando phantom) was utilized for woman simulation. For 
each patient the Rando phantom TC-scan was matched with 
the PET/CT. Doing it, an approximate patient specific 
isocenter position on the Rando phantom and a relative 
position of ovaries and uterus in terms of phantom slices 
were identified. Treatment planning images and diagnostic 
whole body PET/CT were fused by means of Velocity AI 3.0 
®. Calcium fluoride thermoluminescent dosimeters, TLD-100, 
were used for dose measurements, 5 TLDs were used for 
every measurement. Patient’s treatment was simulated in 4 
different techniques: 3DRT, IMRT, VMAT and helical IMRT- 
Tomotherapy®. To compare the results paired T student test 
was used. 
 
Results: The equivalent doses to left ovary, right ovary and 
uterus, were respectively 16 mSV (range 5-19), 10 mSV (range 
8-14) and 9 mSV (range 7-12) with 3DRT techniques; 15 mSV 
(range 7-23), 11.5 mSV (range 6-17) and 13 mSV (range 6-18) 
with VMAT; 14 mSV (range 6-23), 14 mSV (range 5-22) and 13 
mSV (range 9-20) with IMRT and 54,5 mSV(range 44-70), 
50mSV (range 40-72) and 56 mSV (range 33-67) with helical 
Tomotherapy®. Helical Tomotherapy® doses were 
significantly higher than the other three (p<10-8 for all three 
tests). IMRT results were significantly higher than VMAT and 
3D (p=0,023 and 0,004 respectively). VMAT and 3D results are 
not statistically different one from each other (p=0,42). 
 
Conclusion: All the techniques give a dose to ovary and 
uterus well below 100 mSv. This is the dose considered safe 
in terms of deterministic effects on embryo or foetus and 
with a relatively low risk of stochastic effect. Helical 
Tomotherapy® and IMRT give higher gonads dose as 
compared to other techniques. The implications of these data 
may be relevant also for patients in the very early stages of 
their pregnancy. 
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Purpose or Objective: The main interest was to decrease the 
localization CBCT scan dose in lung area since the dose 
deposited by CBCT contributes fully in increasing low dose 
volume in lung which is arguably the main indicator of 
radiotherapy induced pneumonitis and fibrosis. Several 
scanning protocols with decreasing dose were investigated to 
confirm that the localization accuracy is not reduced. 
 
Material and Methods: In this work it was investigated how 
do physical scanning parameters - voltage, current and time - 
affect the automatic image registration of the localization 
CBCT using XVI 4.5 system from Elekta. A Cathphan 504 
phantom was used for image quality measurements and an 
anthropomorphic phantom PBU-50 was used to verify 
localization accuracy. 21 scanning protocols with decreasing 
dose and two different automatic registration algorithms 
(Grey value and Bone) were analysed in lung area. Deliberate 
shifts with different size and direction were introduced. 
Image quality of acquired scans was analysed using modular 
transfer function (MTF), uniformity and low contrast 
visibility. Relative scan dose was measured with centered 
Farmer chamber. 
 
 
 
Results: It was found that CBCT system is rather insensitive 
to the size (max 20 mm) and direction of the deliberate shift 
of the phantom. Precision of the correction shifts were within 
0,5 mm that is in the limit of estimated uncertainty. It was 
observed that the MTF was insensitive to physical scanning 
parameters and much more dependant on image 
reconstruction protocol parameters. Uniformity improved and 
low contrast visibility decreased while lowering dose of 
scanning protocol. The CBCT system under investigation 
showed excellent precision for positioning the phantom even 
while dose of scanning protocol was reduced ~90%. On the 
other hand – low contrast visibility decreased and would most 
likely limit the amount of dose redaction to acceptable level 
that is still to be determined. 
 
Conclusion: This work showed that CBCT is a very accurate 
localization method even in conditions where scanning dose 
was decreased to ~10% of initial dose. It is necessary to 
further assess the suitability of new low dose protocols 
qualitatively to develop acceptable clinical scanning 
protocols as well as to investigate possibility to improve 
reconstruction protocols. 
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Purpose or Objective: To construct a data warehouse of 
radiotherapy imaging performance data by automatically 
extracting CT and CBCT acquisition and dose information 
from the hospital PACS and ARIA oncology management 
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system (OMS), thus allowing individual patient dose records 
to be monitored and radiotherapy imaging dose reference 
levels (DRLs) to be developed. 
 
Material and Methods: DICOM query/retrieve is used to index 
and fetch CT dose report objects known to the PACS. 
Protocol information, patient details, CTDI and DLP are 
extracted. A script runs against the OMS and extracts CBCT 
activity information, including exposure settings and scan 
length. All information is converted into a standard format 
and stored in a data warehouse structured to make data 
exploration straightforward using readily available reporting 
and data mining tools. Data can be plotted and tabulated as 
a function of scanner, linac, operator, day of week, etc. 
Authorised operators can drill down to the patient, study and 
series level to understand the pre-treatment and linac 
imaging performed on individual patients and review the 
overall imaging dose record. Data can also be presented 
anonymised or pseudonymised for research, development and 
audit purposes. 
 
Results: Table 1 shows data volumes and extract timings for 
a large centre (8 linacs with CBCT). The processing burden to 
update the data warehouse on a nightly basis is negligible. 
 
Radiotherapy pre-treatment exposures were consistent with 
the equivalent diagnostic investigations and both were in line 
with local and national DRLs. There was clear evidence that 
when more advanced and automated linac imaging 
equipment is available more CBCTs are acquired (linacs VT1 
and VT3 in Figure 1). Optimisation strategies can be studied 
by reviewing dose information alongside image quality and 
clinical decision making (see Figure 2, where dose differs 
between linacs and was deliberately increased when imaging 
a large patient). 
 
 
It was found that ARIA does not always correctly record CBCT 
exposure information, although if linac imaging is protocol 
driven there is a unique relationship between recorded values 
and protocol selected. Also, body site information may be 
coded differently between CT scanners. Data warehouse 
mapping tables were employed to identify the actual CBCT 
protocols utilised and standardise site descriptions. 
 
Conclusion: An automated data warehouse empowers 
professionals who are not IT experts to ask clinically relevant 
questions of a rich data source of imaging performance and 
dose information. 
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Purpose or Objective: Radiosurgery (SRS) and stereotactic 
radiotherapy (SRT) are known to deliver very high doses per 
fraction. The corresponding peripheral dose can be a limiting 
parameter which potentially generates late toxicities. The 
purpose of this study was to evaluate peripheral dose 
delivered to healthy tissues such as thyroid and gonads for 
brain SRS/SRT treatments performed with a Cyberknife® 
M6TM system. 
 
Material and Methods: Measurements were performed on a 
Cyberknife® M6TM (Accuray) equipped with fixed and IrisTM 
collimator systems. Doses were measured with GR200A 
(LiF:Mg, Cu, P) thermoluminescent dosimeters (TLD). Each 
TLD was individually calibrated in a 6 MV beam. TLD readings 
were performed with a PCL3 automatic reader (FIMEL). 
Firstly, in-vitro measurements were carried out in an 
anthropomorphic phantom (CIRS ATOM 701-c) for different 
typical brain treatment plans using different beam apertures 
(5 mm to 60 mm). Peripheral doses were measured at 24 
points distributed from thyroid to gonads on the median line 
of the phantom (between 15 cm and 82.5 cm from the PTV 
center). Secondly, in-vivo measurements were performed on 
30 patients, in 4 points representative of thyroid, breast, 
umbilicus and gonads. The number of monitor units (MU) used 
for treatment plans ranged from 5499 MU to 28900 MU with a 
mean value of 13737 MU, delivered in 1 to 3 fractions. 
Results were compared with peripheral dose published for 
previous Cyberknife® versions. Treatment plans were 
calculated with Multiplan v5.1.2 (Accuray). Peripheral dose 
were reported in cGy as percentage of the number of 
delivered Monitor Units (% of MU). 
 
Results: Peripheral dose varied according to collimator size: 
0.043 % of MU at 15 cm for a 5 mm collimator aperture and 
0.235 % of MU at 15 cm for a 60 mm collimator aperture. For 
an intermediate collimator aperture (20 mm), peripheral 
doses were between 0.062 % of MU at 15 cm and 0.036 % of 
MU at 40 cm for fixed collimator system and between 0.040 % 
of MU at 15 cm and 0.029 % of MU at 40 cm for IrisTM 
collimator system. Table 1 compares our in-vivo 
measurements with peripheral dose published in the 
literature on several Cyberknife® models [1,2]. 
 
 
 
